{"ticker": {"uuid": "cdb1cc00-bd5f-4539-a8f0-1405d7e05e7e", "symbol": "ORGO", "name": "Organogenesis Holdings Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/organogenesis-holdings-inc-report-second-113000952.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis schedules Aug. 6 results call after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPT1ZSeTM0R3RfcUtXR1NvTzMwWEtvSkNXdmlHeFpjQ3VlT0tFbHY1SExqcHNJRjhlcV9mQWIxbVhiMVg0YlgzbENWb2s3OGJQZk5ERlMxeUVXXzU1ZURpeHFOMWlISWlleFRzWGo2UXM5bXAxdEUxRUUyOTQyQTVrTXZHRngxZndBbU54c05BM0hYUmdzek1iRFlVdUJfal96bmpaVDBWLWJTN2UtSGFESkx4OXRkNnM0b3dfZ0JB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOeV80Q1dSNVg2WXZuVFpfVGhhM1M2QS1ldGFvUWl3Q2N4NGhEUkdwRGlRaEttU1lubllzdEU4a1VMOE9HMHlHeU1DLWFLbTJBUVREZXhIYmQ0a0U0ZmJsQXFESUY4M2hxZkt0R3BWcW5SWV9YeDh1dm9LekUyUXFldGk3cktvQ2pkR3RncDBGX25SbnduZkt5V3IzclE3aG9RVkNfZGJMRlpvbnV2WHB6eDIzUElVbzFHUUNSOWFEMDBuY1hzYlg0LUtR?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T17:57:59+00:00", "published_display": "07 Jul 2026 17:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu\u00ae for the Management of Symptomatic Knee Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/organogenesis-announces-fda-acceptance-biologics-200500709.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:05:00+00:00", "published_display": "06 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNOGs4V0t0Qms5TlN1Ym5ZYVpXLTdqRW1Mdy0zek9Pc202U19CSjVpYjRmQVYxTjFzdmVLVFZSVHA2bjZscVQ5WFlIOGNFeHAwNU9ERXBtLUh3Q2Q2Umo5VVZEa1g1YXpPTzgzb1hYV25CWlpnZWdBZEJZMlJTeUhsd2Y4cFVlTWJFYlR4MlFNeW1MeVBPODlPbFczSGFvNGF3RVRuWDNGeWVoX2UybUhuVnRqMHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Organogenesis Holdings, Inc. Class A \u2013 LSX:A2PA31", "summary": "This article provides the \"Price to earnings forward\" value for Organogenesis Holdings, Inc. Class A (LSX:A2PA31). It indicates the period, value, and change percentage, noting that the data was made by humans. The article is a financial data point from TradingView.", "url": "https://www.tradingview.com/symbols/LSX-A2PA31/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:39:11", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORGO SEC Filings - Organogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Organogenesis Holdings Inc. (ORGO) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. Recent filings highlight a significant downturn in Q1 2026 financial performance, with an 58% ", "url": "https://www.stocktitan.net/sec-filings/ORGO/", "source_name": "Stock Titan", "published_at": "2026-06-29T18:39:49", "published_display": "29 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A \u2013 LSX:A2PA31", "summary": "This article provides the enterprise value to EBIT forward for Organogenesis Holdings, Inc. Class A, traded on the Lang & Schwarz Exchange under the symbol A2PA31. It appears to be a financial data point from a trading platform without additional commentary or analysis.", "url": "https://www.tradingview.com/symbols/LSX-A2PA31/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:13:50", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO)", "summary": "The article provides actuals and estimates for Organogenesis Holdings Inc. (ORGO) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers earnings, revenue, EBITDA, and employee count, alongside answers to frequently asked ques", "url": "https://www.tradingview.com/symbols/NASDAQ-ORGO/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:40:39", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay", "summary": "Organogenesis Holdings Inc. (NASDAQ: ORGO) shareholders reelected the entire board of directors, approved executive compensation on an advisory basis, and ratified RSM US LLP as their independent registered public accounting firm at their 2026 Annual Meeting. All nine director no", "url": "https://www.stocktitan.net/sec-filings/ORGO/8-k-organogenesis-holdings-inc-reports-material-event-50e3a8b8c89d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:41:46", "published_display": "16 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOanFiUVozS0dGREYzdVVaTEtpamxkM1VFMEZVX1J3Z3FuSDJHUU40WmJaRGN5b2F2RVgzbmdncmlJSUNhdmgzSjhZMXh6V0NEdUFRR2pwWEFya3NGWWtIN19rTjBkbGhlVkJtUmpxRjRfUEpPWUhseUhkdG1kcUxtaUNGdlRMUDh5OVFMeEVOX3Jnb0cyVk9GckxlTWVsX1dXbnFsbEtFRXA2LXdGNzhWUThyZFpZMEZfY3hoWTlwak80dGE0d0lRa1Q4RHY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Organogenesis Holdings, Inc. Class A \u2013 DUS:2PQ", "summary": "This article provides general information about Organogenesis Holdings, Inc. Class A (DUS:2PQ) on the Dusseldorf Stock Exchange. It notes that the market is currently closed and briefly touches on data sources and copyright information related to the financial data presented. The", "url": "https://www.tradingview.com/symbols/DUS-2PQ/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-01T23:10:22", "published_display": "01 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist initiates Organogenesis stock at Hold on reimbursement shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOM2ZiZFdNcm9DMDRWRnVldFVrdTRhRWFJYXJCRHE3OGNha1ptOVFaek81WUx2OWJab21qUkR0QzlaOGhCczg0WnI5ZENjVnRNMHl3THpGZ1dZenVSUHJ1YWVsVzVqMWdQdXBCeWxkWjlpZm93V3NhSFVXUEdEN1pxOU0tcXpmOW1HRVpacTI0eEpOYkE0N05BSnV5dnBnaFIySWJKbmJaVGFaeWo3cVZiTDJxcTJNQWtSR3ZCQ2gwT0hWQXAxQ1d3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeC1PQnByR0dSQjk4eDQyWEJiY3VxZnI1UXFrQXlBYzJVYXpZZWsyaUZsdHV0a2ViUXNIU08zcWVBNUNmVzdSZnZDY3Z6Ym84MzZkU2o0NWxJbDRQMkNIbTlIbTB3UFF3c01JWWw0VnU3aGhhalVIbTJXM0Q2ZElSVVk3bjVlbnFjTjZ6dWtkWWQyMWxUcnlGbzNJeHRkeGc1dWpwQ1ZpRXJIbmM?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) posts 58% Q1 revenue drop and deeper loss", "summary": "Organogenesis Holdings Inc. reported a significant downturn for Q1 2026, with net product revenue plunging 58% to $36.3 million, primarily due to a 63% drop in Advanced Wound Care revenue. The company's net loss widened to $53.2 million, or $(0.44) per share, compared to a $18.8 ", "url": "https://www.stocktitan.net/sec-filings/ORGO/8-k-organogenesis-holdings-inc-reports-material-event-cc2890d8d462.html", "source_name": "Stock Titan", "published_at": "2026-05-18T22:10:54", "published_display": "18 May 2026 22:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. - Class A (NQ: ORGO)", "summary": "This article provides recent news headlines related to Organogenesis Holdings Inc. - Class A (ORGO), though most of the listed articles are from April 2021 and discuss other companies like Repligen, Quanterix, Reviva Pharmaceuticals, Align Technology, Novocure, and various biotec", "url": "https://markets.financialcontent.com/stocks/quote/news?Symbol=NQ%3AORGO&CurrentPage=10&CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-15T08:39:02", "published_display": "15 May 2026 08:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/cea8be1e-0fbf-323d-87eb-1e3e708124b6/organogenesis-%28orgo%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T17:28:17+00:00", "published_display": "08 May 2026 17:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/b631a67a-1572-37c3-a1e7-1849ec85737d/organogenesis-holdings-inc..html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOaUZXUEpYZmV6Skw1LXo0dW5QNjN5WWI5eG1FM0xWaXg5V0YxeUNsRS1vbUt3ZjJpYVExZkI5cTdDaDBqblRmSllveXJIWmpzOHFoV2Y1Rk5UZXdvZmsybGlJNkNqS0RNdnoxLTVGdncxYWF5VDFQN0p6SmwxVFJRZE9QZkFfemlNRy00VnY0WHdEWDhhMXlUUnNQXzRKQ2dmaDlKRVNxc3ZIek5Kc1Fn?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/organogenesis-q1-earnings-snapshot-214913996.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:49:13+00:00", "published_display": "07 May 2026 21:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/organogenesis-holdings-inc-reports-first-200500721.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "31.1M Americans have knee OA; Organogenesis sends ReNu to FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOOVViT3RSRms5RXgyWXd1TTFIdHREczRTOEkyNldwUVNiZnRZRTQ2RUF4SlpUR2hWcUR1NnFNTEdzRUNObEFpdGhCLWxSWVJ4QWt1R2V3eUxNbnZGMndPS1hrSnQtMlZ4UTNFeHhMZzB1THZrVkhVYmF6ZDRoTXl4blVDZXZBcTljQUJHNjJDdmxDQjFINE92RTA1WEFNRGZCTXJ1WkF0aElDZnRSeXg4OEhpSDM2TFB3VXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) CCO exercises option, now holds 900,682 shares", "summary": "Organogenesis Holdings Inc.'s Chief Commercial Officer, Brian Grow, exercised stock options to acquire 958 shares of Class A Common Stock at $1.24 per share on January 10, 2025. This transaction increased his direct holdings to 900,682 shares. The Form 4 filing indicates a neutra", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-e0ae3c75fea5.html", "source_name": "Stock Titan", "published_at": "2026-04-25T01:38:45", "published_display": "25 Apr 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm", "summary": "The Portnoy Law Firm has announced an investigation into Organogenesis Holdings, Inc. for potential securities fraud, encouraging investors to contact them to discuss legal rights and options for recovery. This follows a significant 10.14% stock price drop on December 30, 2025, a", "url": "https://www.globenewswire.com/fr/news-release/2026/04/15/3274490/0/en/Organogenesis-Holdings-Inc-Investigated-by-the-Portnoy-Law-Firm.html", "source_name": "GlobeNewswire", "published_at": "2026-04-16T08:39:09", "published_display": "16 Apr 2026 08:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Organogenesis Stock On Wednesday?", "summary": "Organogenesis Holdings Inc. (NASDAQ: ORGO) shares are up in premarket trading on Wednesday due to positive clinical trial results for its PuraPly AM product, which showed statistically significant wound closure for diabetic foot ulcers. The company also confirmed plans to submit ", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-organogenesis-stock-on-wednesday-2026-04-08", "source_name": "Sahm", "published_at": "2026-04-09T07:09:46", "published_display": "09 Apr 2026 07:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newmark brokers Lightstone\u2019s $68 million acquisition of 122,507 s/f 100 Technology Way", "summary": "Lightstone, a leading real estate company, has acquired 100 Technology Way in Smithfield, RI, for $68 million, expanding its life science portfolio. The 122,507 s/f Class A cGMP biomanufacturing facility is fully leased to Organogenesis, who is investing $100 million in renovatio", "url": "https://nerej.com/newmark-brokers-lightstones-68-million-acquisition-of-122507-sf-100-technology-way", "source_name": "NEREJ", "published_at": "2026-04-08T16:40:41", "published_display": "08 Apr 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis stock surges 20% on trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOT0FOd1NJOE5vZkMtZTdGbG9pMmItM0ZnVVNyb1hpUkJld0hKcEt2RzBoQTlDSkMxWVJnRm0yVk5BM3Jtdk9YeFVMRE9HQUxBcUtNd3J3WEd2SE1ZTG1ha0s1VXF0UzZlZTRzR1dCNHBhYl9mQk1SOFMtNE1ISVFjeWR1R01MR2dNMXdwRXFHY0QyMHEybWFTaFlBLXRMdFlINWdPVjYtNVQ1YlZa?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTExxc1NEczE5bndUV3hMTkNrbG1YTHAzeEFzSjJjd01uN0VkV3h2bjNEa1VKX21IRnR1TlkzdlhHVllOVXlfaGgzcWtjWVphNS13MEFOYVJCRTBJeWZiZDI2UWtOdlZiai03ci1YLW0tSWtnT3FqNDhJNU5JVHozd2RUc3FLR2tLV1lTOHVEMlV1dXNFUDJrYWJrLU5lTUs0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis\u2019 Clinical Trials Propel Stock Amid FDA Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQd0pSZzRSQUlJYjBDeFY1d2VLeHdiNDJ3bjFQa1VjWXBQeng1QjBTVnMzbjdJQ0RVU1pRbkZ1TVZsNkx5R0V5SkZsNzlYeFlRMUZ5YWV2X09XbXVWUEVGdGNmN09FSFplemVOdHhPRS1wLU84U2xHNXkxNE5DQ2VXMjdYMzRoMDJ4TUE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis stock up as PuraPlyAM succeeds (ORGO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNcTl0MXd2YXJyNGkwT2VYajNLLW5GQkJ6STZIS1N6MmR1SUJVZHhhVVpHS01GUm9YVkZqcDVrd1hsUUpmTnQxZmlqSFJvLTduQmd1YUxDMGNmTTExb1A3bWR2RzJ4RndKVzNZak1KOEhoSS0zazdlQXBmeS14WmRmSmpUaVpXUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy", "summary": "Organogenesis has received clearance to initiate a rolling Biologics License Application (BLA) for its ReNu therapy, designed to treat knee osteoarthritis. This announcement follows a successful meeting with the FDA, and the company plans to submit the BLA for their ReNu product,", "url": "https://www.marketscreener.com/news/organogenesis-cleared-to-begin-rolling-bla-for-renu-knee-osteoarthritis-therapy-ce7e51d3d88af127", "source_name": "marketscreener.com", "published_at": "2026-04-06T17:59:00", "published_display": "06 Apr 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis to discuss Q1 results and corporate update May 7", "summary": "Organogenesis Holdings Inc. (Nasdaq: ORGO) will report its first-quarter fiscal year 2026 financial results after market close on May 7, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a c", "url": "https://www.stocktitan.net/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-8vks543e4bvv.html", "source_name": "Stock Titan", "published_at": "2026-04-06T16:10:29", "published_display": "06 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In 170-patient diabetic foot ulcer study, Organogenesis clears key goal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMHkydGgtOWYzNTk5MUhjLVk4TlF6a09mUXBaRTB1SWhmeWFFNk1KYTE1TG80VWhJeTc0dnZjUU80Q3RZeVhUbGlya0h3aWY4cEd6bU1yaE5mS3JuOUVvMGZteVpPZUdRa2phNEpEYUFqRGF4cEZJX0pxTUhfU05YbWh0NzlXYkNFYW4wX1RCMUFuRUdjckJxN2tLYlo4SGJjMnk4TzlSUHltLTZ5akp1MER1dmg3bncyYmhv?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes (NASDAQ:ORGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNnBNRkphQ2lhUjdzQV95OUI1WTlNeGx6QjVWSlNybWR6dE1JQUpuRnEzOHdrU2tMMUdjbV9kaWktZElybkxNUV9HdDJCTFduS01GaWN4OUg0UUhfdDB6Skg0cUItUHRYWXVrbGF1dVBwZXFGX3VwQjRlUHF0T091dUdVaElhLThjVHM0UTBoMk9YM2d5MkUyZktOZS1TV0ttVmFxWjNBNlluUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Organogenesis (NASDAQ: ORGO) purchases 5,000 shares", "summary": "Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at $2.681 per share on March 9, 2026. This transaction increased his directly held stake to 291,014 shares. The purchase, detailed in an SEC Form 4 fi", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-ad02ce2eb97e.html", "source_name": "Stock Titan", "published_at": "2026-03-12T21:09:01", "published_display": "12 Mar 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) director adds 10,000 shares in open-market purchase", "summary": "Organogenesis Holdings Inc. director Michael Joseph Driscoll purchased 10,000 shares of Class A Common Stock in an open-market transaction on March 9, 2026. He bought the shares at approximately $2.67 per share, totaling around $26,688. This purchase increases his direct ownershi", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-ed6ee8ccee55.html", "source_name": "Stock Titan", "published_at": "2026-03-12T08:40:04", "published_display": "12 Mar 2026 08:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis director Leibowitz buys $13k in ORGO stock", "summary": "Arthur S. Leibowitz, a director at Organogenesis Holdings Inc (NASDAQ:ORGO), purchased 5,000 shares of Class A Common Stock for $13,405. This insider buying occurred as ORGO stock trades near its 52-week low, and an InvestingPro analysis suggests the stock is undervalued and in o", "url": "https://www.investing.com/news/insider-trading-news/organogenesis-director-leibowitz-buys-13k-in-orgo-stock-93CH-4556007", "source_name": "Investing.com", "published_at": "2026-03-12T07:53:04", "published_display": "12 Mar 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) VP uses 700 shares to cover tax withholding", "summary": "Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, reported a tax-related transfer of 700 Class A common stock shares at $3.21 each to cover tax withholding obligations. This transaction leaves him with 275,524 direct shares. This was not a traditional buy or sell but ", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-12e327caa468.html", "source_name": "Stock Titan", "published_at": "2026-03-07T07:52:10", "published_display": "07 Mar 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity", "summary": "This article reports on an amended insider trading activity for Organogenesis Holdings Inc. (ORGO). The company's Chief Financial Officer, Francisco David, filed an amended Form 4 correcting the share counts for an equity award vesting and related tax withholding, which occurred ", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-5cfaa664d627.html", "source_name": "Stock Titan", "published_at": "2026-03-05T12:09:35", "published_display": "05 Mar 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares", "summary": "Organogenesis Holdings Inc. Chief Administrative and Legal Officer, Lori Freedman, filed an amended Form 4 to correct previously reported figures regarding her insider holdings. The amendment clarifies that she acquired 43,212 shares of Class A common stock from a performance sha", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-729117696dbe.html", "source_name": "Stock Titan", "published_at": "2026-03-03T21:51:53", "published_display": "03 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares", "summary": "Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, filed an amended Form 4 to correct details regarding a performance share award. The filing clarifies the number of Class A Common Stock shares acquired upon vesting (16,454) and shares withheld for tax obligations (5,4", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-8dd70430a652.html", "source_name": "Stock Titan", "published_at": "2026-03-03T21:51:53", "published_display": "03 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu\u00ae to Address Knee Osteoarthritis Pain", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdUhnM0FyWGIzZEMwckdDR0FMVlBHYnhuMzlEeGV1bGk4ZmhjMTZPWWhHVXUzWkNTU2xnSlJRM1FQSUtjQm9pZllFLVlyOVc5ZDNXalpLM2F1YWNvdzRDRnYySEo2NFFTTjRpNDJsUGJOWVJiWlA3WUdycmpjSXh1X1BRMVljc2QyMFl5MDdqY01IUkJmUHQ5WHhvLUhKQ2xiQktGRlExaWNpZ0JjcEV0dTNWMlpUUTFjdktkU2tSY3JjWG9lT0xqLTRGRloxMlFUNkZPcDMzaEdOSTJJR0NzWk0zWVEzUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Hldgs (ORGO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jbnFWWW1YVEM1TnRDUERNQXF3a1NwUlk4MWtYMERZUE1wNmp0ZVdLNmlSLUdHc0Z3cmh2dzdoQlRxOE9IWUlPYURhYkVFQm04TGd3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:37:16+00:00", "published_display": "25 Apr 2025 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/organogenesis-holdings-inc-report-second-113000952.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis schedules Aug. 6 results call after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPT1ZSeTM0R3RfcUtXR1NvTzMwWEtvSkNXdmlHeFpjQ3VlT0tFbHY1SExqcHNJRjhlcV9mQWIxbVhiMVg0YlgzbENWb2s3OGJQZk5ERlMxeUVXXzU1ZURpeHFOMWlISWlleFRzWGo2UXM5bXAxdEUxRUUyOTQyQTVrTXZHRngxZndBbU54c05BM0hYUmdzek1iRFlVdUJfal96bmpaVDBWLWJTN2UtSGFESkx4OXRkNnM0b3dfZ0JB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOeV80Q1dSNVg2WXZuVFpfVGhhM1M2QS1ldGFvUWl3Q2N4NGhEUkdwRGlRaEttU1lubllzdEU4a1VMOE9HMHlHeU1DLWFLbTJBUVREZXhIYmQ0a0U0ZmJsQXFESUY4M2hxZkt0R3BWcW5SWV9YeDh1dm9LekUyUXFldGk3cktvQ2pkR3RncDBGX25SbnduZkt5V3IzclE3aG9RVkNfZGJMRlpvbnV2WHB6eDIzUElVbzFHUUNSOWFEMDBuY1hzYlg0LUtR?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T17:57:59+00:00", "published_display": "07 Jul 2026 17:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu\u00ae for the Management of Symptomatic Knee Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/organogenesis-announces-fda-acceptance-biologics-200500709.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:05:00+00:00", "published_display": "06 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNOGs4V0t0Qms5TlN1Ym5ZYVpXLTdqRW1Mdy0zek9Pc202U19CSjVpYjRmQVYxTjFzdmVLVFZSVHA2bjZscVQ5WFlIOGNFeHAwNU9ERXBtLUh3Q2Q2Umo5VVZEa1g1YXpPTzgzb1hYV25CWlpnZWdBZEJZMlJTeUhsd2Y4cFVlTWJFYlR4MlFNeW1MeVBPODlPbFczSGFvNGF3RVRuWDNGeWVoX2UybUhuVnRqMHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Organogenesis Holdings, Inc. Class A \u2013 LSX:A2PA31", "summary": "This article provides the \"Price to earnings forward\" value for Organogenesis Holdings, Inc. Class A (LSX:A2PA31). It indicates the period, value, and change percentage, noting that the data was made by humans. The article is a financial data point from TradingView.", "url": "https://www.tradingview.com/symbols/LSX-A2PA31/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:39:11", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORGO SEC Filings - Organogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Organogenesis Holdings Inc. (ORGO) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. Recent filings highlight a significant downturn in Q1 2026 financial performance, with an 58% ", "url": "https://www.stocktitan.net/sec-filings/ORGO/", "source_name": "Stock Titan", "published_at": "2026-06-29T18:39:49", "published_display": "29 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A \u2013 LSX:A2PA31", "summary": "This article provides the enterprise value to EBIT forward for Organogenesis Holdings, Inc. Class A, traded on the Lang & Schwarz Exchange under the symbol A2PA31. It appears to be a financial data point from a trading platform without additional commentary or analysis.", "url": "https://www.tradingview.com/symbols/LSX-A2PA31/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:13:50", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO)", "summary": "The article provides actuals and estimates for Organogenesis Holdings Inc. (ORGO) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers earnings, revenue, EBITDA, and employee count, alongside answers to frequently asked ques", "url": "https://www.tradingview.com/symbols/NASDAQ-ORGO/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:40:39", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay", "summary": "Organogenesis Holdings Inc. (NASDAQ: ORGO) shareholders reelected the entire board of directors, approved executive compensation on an advisory basis, and ratified RSM US LLP as their independent registered public accounting firm at their 2026 Annual Meeting. All nine director no", "url": "https://www.stocktitan.net/sec-filings/ORGO/8-k-organogenesis-holdings-inc-reports-material-event-50e3a8b8c89d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:41:46", "published_display": "16 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOanFiUVozS0dGREYzdVVaTEtpamxkM1VFMEZVX1J3Z3FuSDJHUU40WmJaRGN5b2F2RVgzbmdncmlJSUNhdmgzSjhZMXh6V0NEdUFRR2pwWEFya3NGWWtIN19rTjBkbGhlVkJtUmpxRjRfUEpPWUhseUhkdG1kcUxtaUNGdlRMUDh5OVFMeEVOX3Jnb0cyVk9GckxlTWVsX1dXbnFsbEtFRXA2LXdGNzhWUThyZFpZMEZfY3hoWTlwak80dGE0d0lRa1Q4RHY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Organogenesis Holdings, Inc. Class A \u2013 DUS:2PQ", "summary": "This article provides general information about Organogenesis Holdings, Inc. Class A (DUS:2PQ) on the Dusseldorf Stock Exchange. It notes that the market is currently closed and briefly touches on data sources and copyright information related to the financial data presented. The", "url": "https://www.tradingview.com/symbols/DUS-2PQ/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-01T23:10:22", "published_display": "01 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist initiates Organogenesis stock at Hold on reimbursement shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOM2ZiZFdNcm9DMDRWRnVldFVrdTRhRWFJYXJCRHE3OGNha1ptOVFaek81WUx2OWJab21qUkR0QzlaOGhCczg0WnI5ZENjVnRNMHl3THpGZ1dZenVSUHJ1YWVsVzVqMWdQdXBCeWxkWjlpZm93V3NhSFVXUEdEN1pxOU0tcXpmOW1HRVpacTI0eEpOYkE0N05BSnV5dnBnaFIySWJKbmJaVGFaeWo3cVZiTDJxcTJNQWtSR3ZCQ2gwT0hWQXAxQ1d3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeC1PQnByR0dSQjk4eDQyWEJiY3VxZnI1UXFrQXlBYzJVYXpZZWsyaUZsdHV0a2ViUXNIU08zcWVBNUNmVzdSZnZDY3Z6Ym84MzZkU2o0NWxJbDRQMkNIbTlIbTB3UFF3c01JWWw0VnU3aGhhalVIbTJXM0Q2ZElSVVk3bjVlbnFjTjZ6dWtkWWQyMWxUcnlGbzNJeHRkeGc1dWpwQ1ZpRXJIbmM?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) posts 58% Q1 revenue drop and deeper loss", "summary": "Organogenesis Holdings Inc. reported a significant downturn for Q1 2026, with net product revenue plunging 58% to $36.3 million, primarily due to a 63% drop in Advanced Wound Care revenue. The company's net loss widened to $53.2 million, or $(0.44) per share, compared to a $18.8 ", "url": "https://www.stocktitan.net/sec-filings/ORGO/8-k-organogenesis-holdings-inc-reports-material-event-cc2890d8d462.html", "source_name": "Stock Titan", "published_at": "2026-05-18T22:10:54", "published_display": "18 May 2026 22:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. - Class A (NQ: ORGO)", "summary": "This article provides recent news headlines related to Organogenesis Holdings Inc. - Class A (ORGO), though most of the listed articles are from April 2021 and discuss other companies like Repligen, Quanterix, Reviva Pharmaceuticals, Align Technology, Novocure, and various biotec", "url": "https://markets.financialcontent.com/stocks/quote/news?Symbol=NQ%3AORGO&CurrentPage=10&CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-15T08:39:02", "published_display": "15 May 2026 08:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/cea8be1e-0fbf-323d-87eb-1e3e708124b6/organogenesis-%28orgo%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T17:28:17+00:00", "published_display": "08 May 2026 17:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/b631a67a-1572-37c3-a1e7-1849ec85737d/organogenesis-holdings-inc..html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOaUZXUEpYZmV6Skw1LXo0dW5QNjN5WWI5eG1FM0xWaXg5V0YxeUNsRS1vbUt3ZjJpYVExZkI5cTdDaDBqblRmSllveXJIWmpzOHFoV2Y1Rk5UZXdvZmsybGlJNkNqS0RNdnoxLTVGdncxYWF5VDFQN0p6SmwxVFJRZE9QZkFfemlNRy00VnY0WHdEWDhhMXlUUnNQXzRKQ2dmaDlKRVNxc3ZIek5Kc1Fn?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/organogenesis-q1-earnings-snapshot-214913996.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:49:13+00:00", "published_display": "07 May 2026 21:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/organogenesis-holdings-inc-reports-first-200500721.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "31.1M Americans have knee OA; Organogenesis sends ReNu to FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOOVViT3RSRms5RXgyWXd1TTFIdHREczRTOEkyNldwUVNiZnRZRTQ2RUF4SlpUR2hWcUR1NnFNTEdzRUNObEFpdGhCLWxSWVJ4QWt1R2V3eUxNbnZGMndPS1hrSnQtMlZ4UTNFeHhMZzB1THZrVkhVYmF6ZDRoTXl4blVDZXZBcTljQUJHNjJDdmxDQjFINE92RTA1WEFNRGZCTXJ1WkF0aElDZnRSeXg4OEhpSDM2TFB3VXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) CCO exercises option, now holds 900,682 shares", "summary": "Organogenesis Holdings Inc.'s Chief Commercial Officer, Brian Grow, exercised stock options to acquire 958 shares of Class A Common Stock at $1.24 per share on January 10, 2025. This transaction increased his direct holdings to 900,682 shares. The Form 4 filing indicates a neutra", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-e0ae3c75fea5.html", "source_name": "Stock Titan", "published_at": "2026-04-25T01:38:45", "published_display": "25 Apr 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm", "summary": "The Portnoy Law Firm has announced an investigation into Organogenesis Holdings, Inc. for potential securities fraud, encouraging investors to contact them to discuss legal rights and options for recovery. This follows a significant 10.14% stock price drop on December 30, 2025, a", "url": "https://www.globenewswire.com/fr/news-release/2026/04/15/3274490/0/en/Organogenesis-Holdings-Inc-Investigated-by-the-Portnoy-Law-Firm.html", "source_name": "GlobeNewswire", "published_at": "2026-04-16T08:39:09", "published_display": "16 Apr 2026 08:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Organogenesis Stock On Wednesday?", "summary": "Organogenesis Holdings Inc. (NASDAQ: ORGO) shares are up in premarket trading on Wednesday due to positive clinical trial results for its PuraPly AM product, which showed statistically significant wound closure for diabetic foot ulcers. The company also confirmed plans to submit ", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-organogenesis-stock-on-wednesday-2026-04-08", "source_name": "Sahm", "published_at": "2026-04-09T07:09:46", "published_display": "09 Apr 2026 07:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newmark brokers Lightstone\u2019s $68 million acquisition of 122,507 s/f 100 Technology Way", "summary": "Lightstone, a leading real estate company, has acquired 100 Technology Way in Smithfield, RI, for $68 million, expanding its life science portfolio. The 122,507 s/f Class A cGMP biomanufacturing facility is fully leased to Organogenesis, who is investing $100 million in renovatio", "url": "https://nerej.com/newmark-brokers-lightstones-68-million-acquisition-of-122507-sf-100-technology-way", "source_name": "NEREJ", "published_at": "2026-04-08T16:40:41", "published_display": "08 Apr 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis stock surges 20% on trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOT0FOd1NJOE5vZkMtZTdGbG9pMmItM0ZnVVNyb1hpUkJld0hKcEt2RzBoQTlDSkMxWVJnRm0yVk5BM3Jtdk9YeFVMRE9HQUxBcUtNd3J3WEd2SE1ZTG1ha0s1VXF0UzZlZTRzR1dCNHBhYl9mQk1SOFMtNE1ISVFjeWR1R01MR2dNMXdwRXFHY0QyMHEybWFTaFlBLXRMdFlINWdPVjYtNVQ1YlZa?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTExxc1NEczE5bndUV3hMTkNrbG1YTHAzeEFzSjJjd01uN0VkV3h2bjNEa1VKX21IRnR1TlkzdlhHVllOVXlfaGgzcWtjWVphNS13MEFOYVJCRTBJeWZiZDI2UWtOdlZiai03ci1YLW0tSWtnT3FqNDhJNU5JVHozd2RUc3FLR2tLV1lTOHVEMlV1dXNFUDJrYWJrLU5lTUs0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis\u2019 Clinical Trials Propel Stock Amid FDA Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQd0pSZzRSQUlJYjBDeFY1d2VLeHdiNDJ3bjFQa1VjWXBQeng1QjBTVnMzbjdJQ0RVU1pRbkZ1TVZsNkx5R0V5SkZsNzlYeFlRMUZ5YWV2X09XbXVWUEVGdGNmN09FSFplemVOdHhPRS1wLU84U2xHNXkxNE5DQ2VXMjdYMzRoMDJ4TUE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis stock up as PuraPlyAM succeeds (ORGO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNcTl0MXd2YXJyNGkwT2VYajNLLW5GQkJ6STZIS1N6MmR1SUJVZHhhVVpHS01GUm9YVkZqcDVrd1hsUUpmTnQxZmlqSFJvLTduQmd1YUxDMGNmTTExb1A3bWR2RzJ4RndKVzNZak1KOEhoSS0zazdlQXBmeS14WmRmSmpUaVpXUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy", "summary": "Organogenesis has received clearance to initiate a rolling Biologics License Application (BLA) for its ReNu therapy, designed to treat knee osteoarthritis. This announcement follows a successful meeting with the FDA, and the company plans to submit the BLA for their ReNu product,", "url": "https://www.marketscreener.com/news/organogenesis-cleared-to-begin-rolling-bla-for-renu-knee-osteoarthritis-therapy-ce7e51d3d88af127", "source_name": "marketscreener.com", "published_at": "2026-04-06T17:59:00", "published_display": "06 Apr 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis to discuss Q1 results and corporate update May 7", "summary": "Organogenesis Holdings Inc. (Nasdaq: ORGO) will report its first-quarter fiscal year 2026 financial results after market close on May 7, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a c", "url": "https://www.stocktitan.net/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-8vks543e4bvv.html", "source_name": "Stock Titan", "published_at": "2026-04-06T16:10:29", "published_display": "06 Apr 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In 170-patient diabetic foot ulcer study, Organogenesis clears key goal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMHkydGgtOWYzNTk5MUhjLVk4TlF6a09mUXBaRTB1SWhmeWFFNk1KYTE1TG80VWhJeTc0dnZjUU80Q3RZeVhUbGlya0h3aWY4cEd6bU1yaE5mS3JuOUVvMGZteVpPZUdRa2phNEpEYUFqRGF4cEZJX0pxTUhfU05YbWh0NzlXYkNFYW4wX1RCMUFuRUdjckJxN2tLYlo4SGJjMnk4TzlSUHltLTZ5akp1MER1dmg3bncyYmhv?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes (NASDAQ:ORGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNnBNRkphQ2lhUjdzQV95OUI1WTlNeGx6QjVWSlNybWR6dE1JQUpuRnEzOHdrU2tMMUdjbV9kaWktZElybkxNUV9HdDJCTFduS01GaWN4OUg0UUhfdDB6Skg0cUItUHRYWXVrbGF1dVBwZXFGX3VwQjRlUHF0T091dUdVaElhLThjVHM0UTBoMk9YM2d5MkUyZktOZS1TV0ttVmFxWjNBNlluUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Organogenesis (NASDAQ: ORGO) purchases 5,000 shares", "summary": "Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at $2.681 per share on March 9, 2026. This transaction increased his directly held stake to 291,014 shares. The purchase, detailed in an SEC Form 4 fi", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-ad02ce2eb97e.html", "source_name": "Stock Titan", "published_at": "2026-03-12T21:09:01", "published_display": "12 Mar 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) director adds 10,000 shares in open-market purchase", "summary": "Organogenesis Holdings Inc. director Michael Joseph Driscoll purchased 10,000 shares of Class A Common Stock in an open-market transaction on March 9, 2026. He bought the shares at approximately $2.67 per share, totaling around $26,688. This purchase increases his direct ownershi", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-ed6ee8ccee55.html", "source_name": "Stock Titan", "published_at": "2026-03-12T08:40:04", "published_display": "12 Mar 2026 08:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis director Leibowitz buys $13k in ORGO stock", "summary": "Arthur S. Leibowitz, a director at Organogenesis Holdings Inc (NASDAQ:ORGO), purchased 5,000 shares of Class A Common Stock for $13,405. This insider buying occurred as ORGO stock trades near its 52-week low, and an InvestingPro analysis suggests the stock is undervalued and in o", "url": "https://www.investing.com/news/insider-trading-news/organogenesis-director-leibowitz-buys-13k-in-orgo-stock-93CH-4556007", "source_name": "Investing.com", "published_at": "2026-03-12T07:53:04", "published_display": "12 Mar 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) VP uses 700 shares to cover tax withholding", "summary": "Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, reported a tax-related transfer of 700 Class A common stock shares at $3.21 each to cover tax withholding obligations. This transaction leaves him with 275,524 direct shares. This was not a traditional buy or sell but ", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-organogenesis-holdings-inc-insider-trading-activity-12e327caa468.html", "source_name": "Stock Titan", "published_at": "2026-03-07T07:52:10", "published_display": "07 Mar 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity", "summary": "This article reports on an amended insider trading activity for Organogenesis Holdings Inc. (ORGO). The company's Chief Financial Officer, Francisco David, filed an amended Form 4 correcting the share counts for an equity award vesting and related tax withholding, which occurred ", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-5cfaa664d627.html", "source_name": "Stock Titan", "published_at": "2026-03-05T12:09:35", "published_display": "05 Mar 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares", "summary": "Organogenesis Holdings Inc. Chief Administrative and Legal Officer, Lori Freedman, filed an amended Form 4 to correct previously reported figures regarding her insider holdings. The amendment clarifies that she acquired 43,212 shares of Class A common stock from a performance sha", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-729117696dbe.html", "source_name": "Stock Titan", "published_at": "2026-03-03T21:51:53", "published_display": "03 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares", "summary": "Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, filed an amended Form 4 to correct details regarding a performance share award. The filing clarifies the number of Class A Common Stock shares acquired upon vesting (16,454) and shares withheld for tax obligations (5,4", "url": "https://www.stocktitan.net/sec-filings/ORGO/form-4-a-organogenesis-holdings-inc-amended-insider-trading-activity-8dd70430a652.html", "source_name": "Stock Titan", "published_at": "2026-03-03T21:51:53", "published_display": "03 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu\u00ae to Address Knee Osteoarthritis Pain", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdUhnM0FyWGIzZEMwckdDR0FMVlBHYnhuMzlEeGV1bGk4ZmhjMTZPWWhHVXUzWkNTU2xnSlJRM1FQSUtjQm9pZllFLVlyOVc5ZDNXalpLM2F1YWNvdzRDRnYySEo2NFFTTjRpNDJsUGJOWVJiWlA3WUdycmpjSXh1X1BRMVljc2QyMFl5MDdqY01IUkJmUHQ5WHhvLUhKQ2xiQktGRlExaWNpZ0JjcEV0dTNWMlpUUTFjdktkU2tSY3JjWG9lT0xqLTRGRloxMlFUNkZPcDMzaEdOSTJJR0NzWk0zWVEzUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Organogenesis Hldgs (ORGO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jbnFWWW1YVEM1TnRDUERNQXF3a1NwUlk4MWtYMERZUE1wNmp0ZVdLNmlSLUdHc0Z3cmh2dzdoQlRxOE9IWUlPYURhYkVFQm04TGd3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:37:16+00:00", "published_display": "25 Apr 2025 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 45, "sentiment_summary": {"positive": 9, "negative": 4, "neutral": 32, "score": 51, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 16.25, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.4, "latest_week": "2026-07-10", "one_week_move": 1.7, "four_week_move": 2.6, "twelve_week_move": -4.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.413921, "market_dynamics_buy_signal": false, "relative_strength": -46.66555, "fair_value_gap": -30.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.0204, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.7% over one week, +2.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "GlobeNewswire", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Seeking Alpha", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Market source", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Ad-hoc-news.de", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.7% over one week, +2.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026"}], "updated_at": "2026-07-16T02:16:30.405675+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}